Keyphrases
Chronic Obstructive Pulmonary Disease
56%
Acute Exacerbation of COPD (AECOPD)
39%
Noninvasive Ventilation
32%
Pseudomonas Aeruginosa (P. aeruginosa)
32%
Hypercapnic Respiratory Failure
30%
COPD Patients
25%
Open-label Trial
24%
Eosinophils
23%
Severe COPD
22%
Pulmonary Rehabilitation
21%
Telerehabilitation
21%
Non-hospitalized
21%
Corticosteroid Therapy
17%
Asthma
15%
Non-cystic Fibrosis Bronchiectasis
15%
Randomized Controlled Trial
15%
Hospitalized Patients
14%
Lung Disease
14%
Pseudomonas Aeruginosa Infection
14%
Hospitalization
14%
Prednisolone
13%
Chronic Obstructive Pulmonary Disease Patient
13%
Pulmonary Disease
13%
Antibiotic Treatment
13%
High Dose
13%
Systemic Corticosteroids
12%
In-hospital Mortality
12%
Steroid Reduction
10%
Trefoil Factor
10%
COPD Readmission
10%
Targeted Antibiotic Therapy
10%
COVID Sequelae
10%
Long COVID
10%
Randomized multicenter Trial
10%
Home Non-invasive Ventilation
10%
Patient Selection
10%
Randomized Clinical Trial
10%
Acute Respiratory Failure
10%
Number of Admissions
10%
COPD Mortality
10%
Screening Data
10%
12-month Follow-up
10%
Multidisciplinary Clinic
10%
Bronchoalveolar Lavage Fluid
10%
Multicenter Randomized Clinical Trial
10%
Chronic Pulmonary Disease
10%
Bone Turnover Biomarkers
10%
University Hospital
10%
Corticosteroid-sparing
10%
Telecare
10%
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
Open-Label Trial
22%
Eosinophil
21%
Pulmonary Rehabilitation
21%
Telerehabilitation
21%
Respiratory Failure
21%
Noninvasive Ventilation
21%
Disease Exacerbation
21%
Randomized Controlled Trial
16%
Corticosteroid Therapy
13%
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
13%
Silo-Filler's Disease
11%
Corticosteroid
11%
Antibiotic Therapy
10%
Trefoil Factor
10%
Lavage Fluid
10%
COVID-19
10%
Sequela
10%
Walking Distance
10%
Noninferiority Trial
10%
Postcovid Syndrome
10%
Bronchiectasis
10%
Asthma
10%
Chronic Lung Disease
10%
Antibiotics
10%
Cystic Fibrosis
10%
Randomized Clinical Trial
10%
Pseudomonas aeruginosa
10%
Prednisolone
10%
Outpatient
8%
Tissue Regeneration
7%
Mucin
7%
Infection
6%
Biological Marker
6%
Quality of Life
6%
Lung Function
5%
Symptom
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
69%
Lung Disease
24%
Respiratory Failure
21%
Pseudomonas aeruginosa
21%
Antibiotics
19%
Cystic Fibrosis
15%
Asthma
15%
Bronchiectasis
15%
Antibiotic Therapy
13%
Antibiotic Agent
13%
Pseudomonas Infection
13%
Chronic Lung Disease
13%
Open-Label Trial
13%
Hospital Mortality
12%
Acute Respiratory Failure
10%
Trefoil Factor
10%
Randomized Clinical Trial
10%
Disease Exacerbation
10%
Noninferiority Trial
10%
Corticosteroid
10%
Randomized Controlled Trial
10%
Prednisolone
8%
Mucin
7%
